597830 Disclosed herein is the use of abiraterone acetate (II) and prednisone in the treatment of prostate cancer, and refractory cancer, and a pharmaceutical composition thereof. Specifically wherein the therapeutically effective amount of abiraterone acetate is from about 50 mg/day to about 2000 mg/day, more specifically 500 mg/day to 1500 mg/day, more specifically 100 mg/day. Additionally wherein the abiraterone acetate is prepared to be administered in at least one oral dosage form comprising 250 mg of abiraterone acetate. Specifically wherein the therapeutically effective amount of prednisone is from about 0.01 mg/day to about 500 mg//day, more specifically from about 10 mg/day to about 250 mg/day.
